In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 records · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog GHRP-6 | ||
|---|---|---|---|
| Identity | |||
| Kind | Small molecule | Synthetic analog | |
| Area | Growth hormone axis | Growth hormone axis | |
| Evidence | |||
| Amount of evidence | 411 | 942 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 14 (12 in people) | 32 (11 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 14 · 5 active | None registered | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 22 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | MK-677 (ibutamoren) | GHRP-6 |
|---|---|---|
| Growth hormone and IGF-1Endocrine and hormones | 12978483 | 377 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026).
| Receptor activity and mechanismReproductive and sexual health | 561244 | 190167122 |
|---|
| Stress hormonesEndocrine and hormones | 241311 | 33258 |
|---|
| Bone and jointMusculoskeletal | 2222 | 1111 |
|---|
| PharmacokineticsPharmacology | 292189 | 221372 |
|---|
| LipidsMetabolic and weight | 21192 | 99 |
|---|
| Adverse eventsWhole body | 99 | 20614 |
|---|
| Glycemic controlMetabolic and weight | 13112 | 183132 |
|---|
| Pituitary hormonesEndocrine and hormones | 8323 | 16943 |
|---|
| SleepSleep | 66 | 963 |
|---|
| Appetite and food intakeMetabolic and weight | 1046 | 2727 |
|---|
| Exercise and physical functionWhole body | 1111 | 33 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
GHRP-6 differs from Ghrelin (human), ghrelin-28 at 5 positions.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 14 trials, ranked by phase, then posted results and enrollment: 1 ongoing · 1 not yet recruiting · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)
Lumos Pharma150 participants20 May 2026 to est. Jan 2028
Growth Hormone Deficiency (GHD)
Lumos Pharma150 participantsest. Feb 2027 to est. Feb 2030
Growth Hormone Deficiency (GHD)
Lumos Pharma104 participants31 Dec 2020 to 4 Sept 2024
Growth Hormone Deficiency
No registered trial that tests GHRP-6 found in ClinicalTrials.gov.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | MK-677 (ibutamoren) | GHRP-6 |
|---|---|---|
| Growth hormone and IGF-1Endocrine and hormonesCompared as: difference from placebo, in ng/ml | 34.42 to 68.44 ng/ml 95% confidence interval for IGF-1 difference Dose studied: 25mg/day24 weeksn = 1232011 | No comparable result 15 randomized-trial results measure it in another way or another unit. |
| SleepSleepCompared as: difference from placebo, in p | < 0.03 p p value for Deviations from normal sleep in young adults Dose studied: 25 mg7 daysn = 81997 | No comparable result 3 randomized-trial results measure it in another way or another unit. |
| Stress hormonesEndocrine and hormonesCompared as: value in the arm that got the peptide, in nmol/l | 47 nmol/L Cortisol increase · MK-677 recipients Dose studied: 25 mg once daily1 yearn not reported2008 | No comparable result 2 randomized-trial results measure it in another way or another unit. |
| Exercise and physical functionMusculoskeletalCompared as: difference from placebo, in w | 12.5 W Mean stair climbing power difference Dose studied: 25mg/day24 weeksn = 1232011 | No randomized trial result 3 results from other study designs. |
| Bone and jointMusculoskeletalCompared as: difference from placebo, in p value | < 0.001 p value P value for Mean serum osteocalcin, all MK-677 groups combined versus placebo at 9 weeks in functionally impaired subjects Dose studied: 5, 10, or 25 mg daily for 2 weeks followed by 25 mg daily for 7 weeks9 weeksn = 911999 | |
| Body compositionMetabolic and weightCompared as: value in the arm that got the peptide, in kg | 1.1 kg Fat-free mass change · MK-677 Placebo: −0.5 kg Dose studied: 25 mg once daily1 yearn = 652008 | |
| Body weightMetabolic and weightCompared as: value in the arm that got the peptide, in kg | 2.7 kg Body weight change · MK-677 Placebo: 0.8 kg Dose studied: 25 mg once daily1 yearn = 652008 | No randomized trial result |
| Appetite and food intakeMetabolic and weightCompared as: difference from placebo, in p value | < 0.05 p value P value for Serum leptin, MK-677 versus placebo at 2 weeks Dose studied: 25 mg/day8 weeksn = 241999 | No randomized trial result 27 results from other study designs. |
| LipidsMetabolic and weightCompared as: difference from placebo, in p value | < 0.001 p value P value for Serum apolipoprotein A-I, MK-677 versus placebo at 2 weeks Dose studied: 25 mg daily8 weeksn = 241999 | No randomized trial result 9 results from other study designs. |
| Sex hormones and fertilityEndocrine and hormonesCompared as: difference from placebo, in unitless | −< 0.05 unitless P value for total testosterone reduction · Shown as a change. The study reports a p value for total testosterone reduction of this size. Dose studied: 25 mg/day8 weeksn = 241999 | No randomized trial result 15 results from other study designs. |
| Thyroid functionEndocrine and hormonesCompared as: difference from placebo, in p value | < 0.05 p value P value for Serum free T3, MK-677 versus placebo at 8 weeks Dose studied: 25 mg/day8 weeksn = 241999 | No randomized trial result 4 results from other study designs. |
| Protein and amino acid metabolismMetabolic and weightCompared as: difference from placebo, in unitless | < 0.01 unitless P value for mean daily nitrogen balance Dose studied: 25 mg once daily7 daysn = 81998 | No randomized trial result |
34.42 to 68.44 ng/ml
95% confidence interval for IGF-1 difference
Dose studied: 25mg/day24 weeksn = 1232011
No comparable result
15 randomized-trial results measure it in another way or another unit.
No randomized trial result 11 results from other study designs. |
No randomized trial result
6 results from other study designs.
16 results from other study designs.
1 result from other study designs.
< 0.03 p
p value for Deviations from normal sleep in young adults
Dose studied: 25 mg7 daysn = 81997
No comparable result
3 randomized-trial results measure it in another way or another unit.
47 nmol/L
Cortisol increase · MK-677 recipients
Dose studied: 25 mg once daily1 yearn not reported2008
No comparable result
2 randomized-trial results measure it in another way or another unit.
12.5 W
Mean stair climbing power difference
Dose studied: 25mg/day24 weeksn = 1232011
No randomized trial result
3 results from other study designs.
< 0.001 p value
P value for Mean serum osteocalcin, all MK-677 groups combined versus placebo at 9 weeks in functionally impaired subjects
Dose studied: 5, 10, or 25 mg daily for 2 weeks followed by 25 mg daily for 7 weeks9 weeksn = 911999
No randomized trial result
11 results from other study designs.
1.1 kg
Fat-free mass change · MK-677
Placebo: −0.5 kg
Dose studied: 25 mg once daily1 yearn = 652008
No randomized trial result
6 results from other study designs.
2.7 kg
Body weight change · MK-677
Placebo: 0.8 kg
Dose studied: 25 mg once daily1 yearn = 652008
No randomized trial result
16 results from other study designs.
< 0.05 p value
P value for Serum leptin, MK-677 versus placebo at 2 weeks
Dose studied: 25 mg/day8 weeksn = 241999
No randomized trial result
27 results from other study designs.
< 0.001 p value
P value for Serum apolipoprotein A-I, MK-677 versus placebo at 2 weeks
Dose studied: 25 mg daily8 weeksn = 241999
No randomized trial result
9 results from other study designs.
−< 0.05 unitless
P value for total testosterone reduction · Shown as a change. The study reports a p value for total testosterone reduction of this size.
Dose studied: 25 mg/day8 weeksn = 241999
No randomized trial result
15 results from other study designs.
< 0.05 p value
P value for Serum free T3, MK-677 versus placebo at 8 weeks
Dose studied: 25 mg/day8 weeksn = 241999
No randomized trial result
4 results from other study designs.
< 0.01 unitless
P value for mean daily nitrogen balance
Dose studied: 25 mg once daily7 daysn = 81998
No randomized trial result
1 result from other study designs.